If regenerative medicine is to fulfil its potential in the years to come it is essential that research protocols are translated into Good Manufacturing Practice (GMP) to allow the production of clinical-grade cellular therapies for clinical trial and eventual clinical practice. SNBTS supports a research and development team lead by Dr John Campbell, Head of RDI, within the SCRM building along with a manufacturing team at the GMP facility led by Dr Neil McGowan to collaborate with academic and clinical colleagues and thereby facilitate this kind of highly specialist translational work.
The SNBTS Cell therapy group is supporting the development of a number of different cellular therapies including (inter alia) corneal epithelial stem cells for ocular surface disorders, anti-EBC cytotoxic T lymphocytes for the treatment of post-transplant lymphoproliferative disease, and mesenchymal stromal cells in pancreatic islet transplantation. SNBTS also provides the management for the Novosang project which is working on the production of red blood cells for clinical transfusion from pluripotent stem cells.
- Jo Mountford, University of Glasgow
- Lesley Forrester, University of Edinburgh
- Rob Thomas, University of Loughborough
- Cedric Ghevaert, University of Cambridge
- David Anstee, NHSBT and University of Bristol
- Willie Murphy, Irish Blood Transfusion Service
- Aidan Courtney, Roslin Cells
- Keith Thompson, Cell Therapy Catapult